Become a
SuperHealer
TM
Eluciderm is advancing a new class of small molecules designed to influence the biological signaling that determines how tissue heals, reactivating regenerative instructions used during the earliest stages of human development, shifting repair away from fibrotic scarring and toward functional tissue regeneration.
We call this capability a Restorative Reset.
Eluciderm's Platform
of Small Molecules
Reprogramming Tissue Repair
Human tissue repair operates through two biological modes: regeneration and fibrotic repair.
During early development, tissue regenerates into fully functional structures. Later in life, healing shifts toward a faster fibrotic response that prioritizes rapid closure but often results in scarring and reduced tissue function.
Eluciderm is developing a platform of proprietary small molecules designed to dynamically modulate the biological signaling that determines how tissues heal.
The Mechanism of Action: Orchestrating PARP Signaling
The platform centers on targeted modulation of Poly (ADP-ribose) polymerase (PARP) enzymes.
PARP enzymes play a critical role in DNA repair, cellular signaling, and stress response pathways that influence how injured tissues respond to damage. These pathways help determine whether tissues heal through regenerative restoration or fibrotic scarring.
Eluciderm’s small molecules are designed to orchestrate PARP signaling, guiding the biological repair response away from fibrosis and toward organized tissue regeneration. We describe this capability as a Restorative Reset.
Restorative Reset
A Restorative Reset aims to reactivate regenerative programs that remain biologically present but largely dormant in adult tissue. Through coordinated PARP signaling, the platform is designed to support organized repair.
Multiple PARP Modulation with Small Molecules.
A multi-dimensional approach to complex tissue repair.
ELU42:
The First Therapeutic
from the Platform
ELU42 is Eluciderm’s lead therapeutic candidate and the first molecule developed from the company’s regenerative repair platform.
ELU42 is designed to locally modulate PARP signaling within injured tissue, helping to influence the cellular repair response at the site of injury.
Skin Regeneration Anywhere / Anytime
Unlike many wound treatments that have focused on oral, intravenous or injectable routes of administration, our patented lead therapeutic candidate ELU42 is formulated as a topical therapy, allowing treatment to be delivered directly to injured tissue while minimizing systemic exposure.
Preclinical studies suggest that topical application of ELU42 supports regenerative repair through a coordinated biological sequence that includes:
-
early suppression of fibrotic signaling
-
increased angiogenesis and vascular support
-
restoration of organized collagen architecture
Together, these effects promote healing that more closely resembles functional tissue regeneration rather than scar formation.
Because ELU42 can be applied directly to wounds, burns, and traumatic injuries, it has the potential to be used across a wide range of clinical environments, including hospitals, surgical settings, and emergency response situations.
Recognition
ELU42, Eluciderm's patented lead therapeutic candidate, has received recognition for its impact in wound care, including the WHS WoundShark Innovation Award at SAWC 2024, where it was recognized for its potential to accelerate healing in chronic wounds, burns, and traumatic injuries.
ELU42, Eluciderm’s leading therapeutic candidate, is currently in a Phase I/IIA clinical trial, called the SuperHealer™ Trial, for Wagner 1 and 2 diabetic foot ulcers (DFUs) and represents the company’s most advanced stage of clinical readiness.
ClinicalTrials.gov ID: NCT07396376; IND169928
